<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899118</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH-ARO2013</org_study_id>
    <nct_id>NCT01899118</nct_id>
  </id_info>
  <brief_title>Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Multicenter Phase II Trial of Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) is now considered as a
      standard treatment of locally advanced rectal adenocarcinomas, which correlates better local
      control and higher sphincter preservation rate. Nimotuzumab, a humanized monoclonal antibody
      against epidermal growth factor receptor (EGFR) has been reported to improve the therapeutic
      effect of radiotherapy in some cancers. This study is a clinical phase II trial designed to
      evaluate the efficacy of the combination of Nimotuzumab administered concurrently with
      neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer, and to further
      investigate its side-effect and toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathology complete remission rate</measure>
    <time_frame>1 year</time_frame>
    <description>Pathology complete remission rate is the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor regression rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sphincter preservation rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>up to 1 month after the last cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative irradiation</intervention_name>
    <description>50.4Gy/28F/5.5w</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>400mg/w，0-5w</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130mg/m2 d1</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825mg/m2 bid d1-5/w,1-5w</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Age:18-75 years

          3. Histologically confirmed locally advanced colorectal cancer (adenocarcinoma)

          4. The lower edge of the tumors located below 12 cm from the anal verge

          5. Karnofsky Performance Scale ≥70 points, Life expectancy ≥ 6 months

          6. No prior chemotherapy was used

          7. No history of regional radiation treatment inthe pelvic cavity

          8. Adequate hematologic function: Hb ≥ 100 g/L , WBC≥3.5×109, ANC ≥ 1.5×109 /L，PLT ≥
             100×109 /L Adequate renal function: Cr ≤ 1.5×ULN, TB≤2.5 × ULN Adequate hepatic
             function: ALT/AST ≤ 2.5×ULN, Alkaline phosphatase ≤ 2.5×ULN

          9. Patients without peripheral neuropathy

        Exclusion Criteria:

          1. Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in
             situ

          2. Rectal cancer patients with concurrent colon cancer

          3. Pregnant or lactating women

          4. Fertile female patients without using any contraceptives

          5. Allergic to cisplatin and fluorouracil

          6. Patients with previous peripheral neuropathy

          7. Serious complications: myocardial infarction, heart failure (NYHA Classification&gt;II
             grade),psychiatric history and severe diabetes

          8. Treatment with other anti-cancer therapy(including Chinese herbal medicine)

          9. Organ transplant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialin Luo, MD</last_name>
      <phone>0086-571-88122062</phone>
    </contact>
    <investigator>
      <last_name>Yuan Zhu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced rectal cancer</keyword>
  <keyword>Neoadjuvant chemoradiotherapy</keyword>
  <keyword>Nimotuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

